Drug intelligence / Profile preview

CF-01

Development stage: Unknown
Lead developer: Cannaflos
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

CF-01 is a phytocannabinoid-based pharmaceutical candidate being developed by Cannaflos for the treatment of neuropathological conditions. The drug is designed to modulate the endocannabinoid system (ECS), a complex cell-signaling network involved in regulating various physiological and cognitive processes. As a cannabinoid-based finished drug product, it utilizes plant-derived compounds to interact with ECS components. CF-01 is currently in Phase 2 clinical development, although the specific molecular targets and the exact neurological indication have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on CF-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF-01.

Explore the full profile